Genesis HealthCare (GEN) Tops Q3 EPS by 12c; Guidance Reaffirmed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Genesis HealthCare Reports Third Quarter 2016 Results
November 3, 2016 4:02 PM EDTAnnounces Planned Divestiture of Facilities in Eight States to Focus on Core Markets
Recently Announced New Leases Reduce Prior Lease Obligation by $440 Million through January 2032 Third Quarter EBITDA Meets First Call Consensus Estimate
KENNETT SQUARE, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Genesis HealthCare (Genesis, or the Company) (NYSE: GEN), one of the largest post-acute care providers in the United States, today announced operating results for the third quarter ended September 30, 2016.Â
... MoreGenmab Announces Financial Results for the First Nine Months of 2016 and Improves 2016 Financial Guidance
November 2, 2016 12:02 PM EDTNovember 2, 2016; Copenhagen, Denmark;
Interim Report for First Nine Months Ended September 30, 2016
Highlights
Net Sales of DARZALEX® (daratumumab) by Janssen for the first nine months of 2016 were USD 372 million, resulting in royalty income of USD 45 million (DKK 298 million)... More